Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2004 Giugno;16(2) > Minerva Biotecnologica 2004 Giugno;16(2):145-9

ULTIMO FASCICOLOMINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

ORIGINAL ARTICLES  CELLULAR AND MOLECULAR ADVANCES IN THE STUDY OF INFLAMMATION


Minerva Biotecnologica 2004 Giugno;16(2):145-9

lingua: Inglese

New ­trends for the devel­op­ment of nov­el ­decoy mole­cules ­against nucle­ar fac­tor kap­pa-B (NF-kB) tran­scrip­tion fac­tor

Gambari R.

1 Biotechnology Center, University of Ferrara, Ferrara, Italy, Interdisciplinary Center for the Study of Inflammation (­ICSI), University of Ferrara, Ferrara, Italy, Department of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy


FULL TEXT  ESTRATTI


Transcription fac­tor ­decoy (TFD) phar­ma­co­ther­a­py ­against nucle­ar fac­tor kap­pa B (NF-kB) pro­teins ­appears to be an impor­tant strat­e­gy for ther­a­py of inflam­ma­to­ry dis­eas­es, ­since NF-kB is deep­ly ­involved in the pro­cess of inflam­ma­tion. In ­this ­short ­review, we ­describe report­ed ­data on the ­effects of pep­tide nucle­ic ­acids (PNAs)-DNA chi­me­ras as TFD mole­cules. These mole­cules are com­posed of a ­part of PNA and a ­part of DNA, ­obey the Watson-Crick ­rules on bind­ing to com­ple­men­tary DNA and RNA and dis­play ­water sol­u­bil­ity. With ­respect to TFD ­approach, prom­is­ing ­results ­have ­been ­obtained ­using dou­ble-strand­ed PNA-DNA chi­me­ras mim­ick­ing the NF-kB and Sp1 bind­ing ­sites ­present with­in the ­long ter­mi­nal ­repeat (LTR) of the ­human immu­no­def­i­cien­cy ­type 1 ­virus (HIV-1). In addi­tion, PNA-DNA chi­me­ras are ­more resist­ant ­than DNA/DNA ­hybrids to nucle­as­es and are suit­able for deliv­ery ­with cat­ion­ic lipo­somes and micro­spheres. In the ­near ­future chi­mer­ic mole­cules ­could be devel­oped ­with ­unique fea­tures, includ­ing ter­mi­nal remov­able pep­tide sig­nals direct­ing inter­nal­isa­tion of the ­decoy mole­cules to select­ed tar­get ­cells and nucle­ar local­iza­tion. These engi­neered mole­cules ­could be of ­great inter­est in in ­vivo experi­ments for devel­op­ment of treat­ment of ­human dis­eas­es asso­ciat­ed ­with NF-kB acti­va­tion, includ­ing sev­er­al inflam­ma­to­ry dis­eas­es.

inizio pagina